Lantern Pharma and Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern’s Artificial Intelligence Platform

- Collaboration Will Leverage Lantern's RADR® A.I. Platform to Accelerate Development of Actuate's Drug Candidate, 9-ING-41 - Actuate's 9-ING-41 is a Best-In-Class Drug Candidate for Cancer & Fibrotic Diseases - Lantern Will Receive Equity Based on Meeting Development Milestones & May Receive Additional Equity Based on Use of Findings in Future Development

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.


Please enter your comment!
Please enter your name here